BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
BD (NYSE: BDX) and Biosero announced a collaboration to integrate robotic automation with BD flow cytometry instruments, aiming to accelerate drug discovery and development processes. The partnership will develop new software capabilities making BD flow cytometer instruments compatible with Biosero's Green Button Go® software.
The integration will automate manual processes in flow cytometry workflows, enabling automatic handling of multiple multiwell plates without human intervention. This automation advancement is particularly significant for biopharma companies and research organizations conducting high-throughput drug screening and cell therapy manufacturing.
The compatible software versions for BD FACSymphony A1, FACSymphony A5 SE, and FACSLyric Flow Cytometry System will be available for research use in 2025. Future integration is planned for the BD FACSDiscover family of instruments.
BD (NYSE: BDX) e Biosero hanno annunciato una collaborazione per integrare l'automazione robotica con gli strumenti di citometria a flusso di BD, con l'obiettivo di accelerare i processi di scoperta e sviluppo di farmaci. La partnership svilupperà nuove capacità software per rendere gli strumenti di citometria a flusso di BD compatibili con il software Green Button Go® di Biosero.
L'integrazione automatizzerà i processi manuali nei flussi di lavoro di citometria a flusso, consentendo la gestione automatica di più piastre multiwell senza intervento umano. Questo avanzamento nell'automazione è particolarmente significativo per le aziende biopharma e le organizzazioni di ricerca che conducono screening ad alta capacità e produzione di terapia cellulare.
Le versioni software compatibili per i sistemi di citometria a flusso BD FACSymphony A1, FACSymphony A5 SE e FACSLyric saranno disponibili per l'uso nella ricerca nel 2025. È prevista un'integrazione futura per la famiglia di strumenti BD FACSDiscover.
BD (NYSE: BDX) y Biosero anunciaron una colaboración para integrar la automatización robótica con los instrumentos de citometría de flujo de BD, con el objetivo de acelerar los procesos de descubrimiento y desarrollo de fármacos. La asociación desarrollará nuevas capacidades de software que harán que los instrumentos de citometría de flujo de BD sean compatibles con el software Green Button Go® de Biosero.
La integración automatizará los procesos manuales en los flujos de trabajo de citometría de flujo, permitiendo el manejo automático de múltiples placas de múltiples pocillos sin intervención humana. Este avance en la automatización es particularmente significativo para las empresas biopharma y las organizaciones de investigación que llevan a cabo cribados de alto rendimiento y fabricación de terapias celulares.
Las versiones de software compatibles para los sistemas de citometría de flujo BD FACSymphony A1, FACSymphony A5 SE y FACSLyric estarán disponibles para uso en investigación en 2025. Se planea una futura integración para la familia de instrumentos BD FACSDiscover.
BD (NYSE: BDX)와 Biosero가 BD 유세포 분석 기기와 로봇 자동화를 통합하기 위한 협력 관계를 발표했습니다. 이 협력의 목표는 약물 발견 및 개발 프로세스를 가속화하는 것입니다. 이 파트너십은 BD 유세포 분석 기기가 Biosero의 Green Button Go® 소프트웨어와 호환되도록 새로운 소프트웨어 기능을 개발할 것입니다.
이 통합은 유세포 분석 워크플로에서 수동 프로세스를 자동화하여 인간의介입 없이 여러 다중 웰 플레이트를 자동으로 처리할 수 있게 해줍니다. 이 자동화 발전은 고처리량 약물 스크리닝 및 세포 치료 제조를 수행하는 생명공학 및 연구 조직에 특히 중요합니다.
BD FACSymphony A1, FACSymphony A5 SE 및 FACSLyric 유세포 분석 시스템을 위한 호환 소프트웨어 버전이 2025년에 연구 목적으로 사용할 수 있을 것입니다. BD FACSDiscover 기계군의 미래 통합도 계획되어 있습니다.
BD (NYSE: BDX) et Biosero ont annoncé une collaboration pour intégrer l'automatisation robotique aux instruments de cytométrie en flux de BD, dans le but d'accélérer les processus de découverte et de développement de médicaments. Le partenariat développera de nouvelles capacités logicielles pour rendre les instruments de cytométrie en flux de BD compatibles avec le logiciel Green Button Go® de Biosero.
L'intégration automatisera les processus manuels dans les flux de travail de cytométrie en flux, permettant la manipulation automatique de plusieurs plaques multi-puits sans intervention humaine. Cette avancée en matière d'automatisation est particulièrement significative pour les entreprises biopharmaceutiques et les organisations de recherche effectuant des dépistages de médicaments à haut débit et de la fabrication de thérapies cellulaires.
Les versions logicielles compatibles pour les systèmes de cytométrie en flux BD FACSymphony A1, FACSymphony A5 SE et FACSLyric seront disponibles à des fins de recherche en 2025. Une future intégration est prévue pour la famille d'instruments BD FACSDiscover.
BD (NYSE: BDX) und Biosero haben eine Zusammenarbeit angekündigt, um robotergestützte Automatisierung mit BD-Flusszytometriegeräten zu integrieren, um die Prozesse der Arzneimittelentdeckung und -entwicklung zu beschleunigen. Die Partnerschaft wird neue Softwarefähigkeiten entwickeln, um die BD-Flusszytometer mit der Green Button Go®-Software von Biosero kompatibel zu machen.
Die Integration wird manuelle Prozesse in Flusszytometrie-Workflows automatisieren, sodass mehrere Multiwell-Platten ohne menschliches Eingreifen automatisch verarbeitet werden können. Diese Automatisierungsfortschritte sind insbesondere für Biopharma-Unternehmen und Forschungsorganisationen bedeutsam, die Hochdurchsatz-Drug-Screenings und Zelltherapiefertigung durchführen.
Die kompatiblen Softwareversionen für die BD FACSymphony A1, FACSymphony A5 SE und FACSLyric Flusszytometrie-Systeme werden für Forschungszwecke im 2025 verfügbar sein. Eine zukünftige Integration für die BD FACSDiscover-Gerätefamilie ist ebenfalls geplant.
- Strategic partnership to automate flow cytometry processes
- Potential increase in efficiency and scalability for drug discovery
- Reduction in manual labor and human error
- New software compatibility expanding product capabilities
- Extended timeline for software availability (2025)
- initial instrument compatibility
Insights
BD's strategic collaboration with Biosero represents a significant advancement in laboratory automation that could substantially impact drug discovery efficiency and BD's market position. The partnership addresses a critical bottleneck in pharmaceutical research by automating the manual handling of multiwell plates in flow cytometry - imagine upgrading from manually changing TV channels to having a smart remote that can program hundreds of channels automatically.
The key breakthrough is the ability to analyze hundreds of sample plates automatically without human intervention, compared to the current one-at-a-time manual process. This automation could lead to:
- Dramatic reduction in labor costs and human error
- Significant increase in testing throughput and speed to market for new drugs
- Enhanced competitiveness in the $8.9 billion global flow cytometry market
The collaboration is particularly well-timed as pharmaceutical companies increasingly focus on cell therapy development and high-throughput drug screening. The planned integration with multiple BD instruments, including the FACSymphony and FACSLyric systems, suggests a comprehensive strategy to capture market share in the growing laboratory automation sector.
While specific financial terms weren't disclosed, this type of automation typically results in 30-50% efficiency gains in laboratory operations. For BD, with its significant presence in the biosciences market, this could translate into stronger competitive positioning and potential revenue growth from both instrument sales and software licensing.
The 2025 launch timeline allows BD to capitalize on the increasing demand for automated solutions in pharmaceutical research, particularly as cell therapy manufacturing scales up and drug discovery processes become more complex. This positions BD at the forefront of the industry's shift toward fully automated laboratory operations.
Together, the companies intend to develop new software capabilities within BD flow cytometer instrument software to be compatible with Biosero’s Green Button Go® software, as well as jointly support biopharmaceutical and contract research organizations with their custom research needs, to enable easy integration with robotic arms.
Traditionally, several steps in a lab’s flow cytometry workflow for drug discovery and development require manual processes. With robotic integration, these steps can become automated. For example, samples are typically loaded and analyzed on a flow cytometer one multiwell plate at a time, requiring a time-consuming manual step each time the multiwell plate is changed. With robotic arm integration, tens or even potentially hundreds of multiwell plates can be automatically changed without human intervention.
“Automation is increasingly paramount for biopharma companies and contract research organizations whose high-throughput drug screening and cell therapy manufacturing efforts rely on the scalability, reproducibility, quality and speed that robotic integration can provide,” said Steve Conly, worldwide president of BD Biosciences. “This collaboration unlocks a new chapter of automation for our current and future biopharma partners. By combining forces with Biosero, a trusted leader in lab automation, we will empower customers to bring their potentially life-changing therapies to market even faster.”
Flow cytometry is a powerful tool used across many stages of drug discovery and development. In drug screening, it allows researchers to analyze effects of potential drug candidates on single cells within vast populations. In cell therapy manufacturing, flow cytometry is used to analyze and characterize cells at different stages of the production process to ensure safety and efficacy of the final cell therapy product.
“Biosero’s portfolio of laboratory automation software works with flow cytometers, robotic arms, as well as mobile robots and other equipment, within one communicative ecosystem, to automate scientific protocols and boost lab productivity while reducing human error,” said Ryan Bernhardt, CEO of Biosero. “This collaboration advances our vision of making laboratory automation easy to use, scalable and adaptable for the vital work of drug discovery and development.”
The new versions of BD flow cytometer instrument software compatible with Biosero automation software for the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer, and BD FACSLyric™ Flow Cytometry System will be available for research use in 2025 through local sales representatives. The BD FACSDiscover™ family of instruments is also on the roadmap for future integration. More information is available at bdbiosciences.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
About Biosero, Inc.
Biosero, a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Biosero’s Green Button Go® Scheduler software and integration services match laboratory automation to science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Additionally, Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. Biosero is passionate about partnering with organizations dedicated to enhancing life by addressing the world’s most significant needs. For more information, please visit www.biosero.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123616589/en/
Media:
Troy Kirkpatrick
VP, Public Relations
858.617.2361
troy.kirkpatrick@bd.com
Suzanne Howard for Biosero
suzanne@bioscribe.com
Investors:
Adam Reiffe
Sr. Director, Investor Relations
201.847.6927
adam.reiffe@bd.com
Source: Biosero, Inc.
FAQ
When will BD's (BDX) automated flow cytometry software be available for research use?
Which BD (BDX) flow cytometer instruments will be compatible with Biosero automation?
How will the BD-Biosero collaboration improve flow cytometry workflows?
What are the main applications of BD's (BDX) automated flow cytometry system?
